The Department of Labor Oct. 29 finalized a rule designed to improve transparency of fees collected by pharmacy benefit managers. The rule requires PBMs to disclose rebates and other payments from drug manufacturers, compensation received when the price paid by a health plan for a prescription drug exceeds the amount reimbursed to the pharmacy, and payments recouped from pharmacies in connection with prescription drugs dispensed to a health plan. The rule also allows plan fiduciaries to audit the accuracy of PBM disclosures and provide additional relief if their PBM fails to meet its obligation. 

Headline
The median annual net launch price for new prescription drugs increased 35% from 2022 to 2025, to $257,000, according to a report released by the Institute for…
Headline
The Centers for Medicare & Medicaid Services Sept. 30 finalized its Global Benchmark for Efficient Drug Pricing Model, also known as the GLOBE Model. The…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 28 that it projects declines in average premiums for Medicare Advantage and Part D in 2027.…
Headline
The Centers for Medicare & Medicaid Services announced Sept. 18 that all 50 states, Washington, D.C., and Puerto Rico have applied to participate in its…
Headline
A survey released Sept. 10 by the National Comprehensive Cancer Network highlights ongoing shortages of cancer medications. All responding cancer centers…
Headline
The Trump administration announced Aug. 31 agreements with nine additional pharmaceutical manufacturers aimed at lowering prescription drug prices through a…